Is Novo Nordisk's Rebound for Real--or Just a Head Fake?

1 hour ago 4

Prosper Junior Bakiny, The Motley Fool

Wed, May 13, 2026 astatine 12:35 PM CDT 3 min read

Novo Nordisk (NYSE: NVO) has importantly lagged the broader marketplace implicit the past 2 years, losing much than 60% of its marketplace value. However, the drugmaker's shares person performed good implicit the past month. The company's caller first-quarter update, released connected May 6, helped propulsion the banal adjacent higher. Can Novo Nordisk prolong this caller momentum?

There are important catalysts up

Novo Nordisk's first-quarter results don't look large connected the surface. The company's adjusted nett income decreased 10% twelvemonth implicit twelvemonth to 70.1 cardinal Danish kroner (about $11 billion). Adjusted net per stock dropped 3% twelvemonth implicit twelvemonth to 6.63 DKK ($1.03). But here's the thing: Novo Nordisk had already projected that its gross and net would diminution this year. The astonishment successful the company's quarterly update was that, though mediocre fiscal results were already baked into the banal price, things weren't astir arsenic atrocious arsenic the marketplace expected. Novo Nordisk tin convey oral Wegovy, which it launched successful January, for that. Oral Wegovy has experienced beardown adoption, with implicit 2 cardinal patients already connected the pill.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Image source: The Motley Fool.

Novo Nordisk's caller rebound could continue, provided it tin marque further headway successful the anti-obesity market. The institution received support for a much effective, high-dose formulation of Wegovy, which could assistance it amended vie with Eli Lilly's Zepbound. Novo Nordisk could besides gain newer approvals -- portion making important objective advancement -- implicit the past 12 months. The institution is awaiting support for CagriSema, its next-gen anti-obesity and diabetes medicine.

Novo Nordisk's pipeline features specified products arsenic Amycretin, an investigational medicine that mimics the enactment of 2 gut hormones: GLP-1 and amylin, some of which assistance power satiety, humor glucose, and different things. Novo Nordisk's pipeline besides features UBT251, a medicine that mimics the enactment of 3 gut hormones and that posted outstanding signifier 2 results successful a objective proceedings successful China. Progress with these programs could jolt the banal implicit the adjacent 12 months. Meanwhile, Novo Nordisk's shares are trading astatine 13.6x guardant earnings, compared to the mean of 16.8x for healthcare stocks.

While the Denmark-based pharmaceutical leader's fiscal results warrant little valuation multiples, its shares could acquisition a sustained tally arsenic it advances its pipeline, adjacent earlier newer products let it to instrumentality to coagulated top-line growth. What does each this mean for investors? Novo Nordisk could execute good implicit the mean term. Although it has mislaid the pb successful the value absorption market, the company's heavy pipeline could let it to capitalize connected this fast-growing country much than astir different drugmakers. And astatine caller levels, the banal inactive looks reasonably valued. In short, Novo Nordisk's rebound whitethorn not beryllium conscionable a caput fake.

Read Entire Article